Insight
Tackling women’s mental health with music and tech

By Tuned Global
Mental health problems affect both men and women, but not in equal measure. According to the Mental Health Foundation, one in five adults has a common mental health condition: about 24 per cent of women and 15 per cent of men.
The Mind Organisation also reveals women are more likely to have suicidal thoughts and to make suicide attempts than men. So how can music therapy help?
At a recent industry event, audiences attending a session on music in the medicine and research space gained insights into the therapeutic benefits of music, such as treating conditions including dementia, Parkinson’s disease, PTSD and ADHD.
Three experts sat down to discuss this exciting and complex space and to explore how in trying to bring these treatments to patients or the broader market, the not-so-common intersection of medtech and music surfaces a number of challenges.
How AI can strengthen music therapies

Felicity Baker
Music therapy itself is not new, and therapists have been delivering such interventions in one-on-one sessions and small groups for decades.
The exciting prospect highlighted during the session was that technology and AI can now enable this at scale and with evidence-based approach.
If more people can gain access to music treatment through technology, there is the potential to decrease medication intake, reduce healthcare costs and improve outcomes.
However, scaling these therapies does introduce new considerations and challenges that traditional clinical settings have not had to face.
Felicity Baker is a music therapist, professor at the University of Melbourne and Founder of Matchplus.ai, a sensor-based AI solution that detects early physiological markers of agitation and delivers personalised music interventions to improve the wellbeing of people living with dementia and other cognitive conditions.
With over three decades of experience in dementia care and music therapy, Baker is leading this project at prototype stage to reduce distress, medication reliance and create a more enabling environment for individuals with cognitive decline.
Having successfully secured USD $1.3m from Google.org (the philanthropic arm of Google LLC) to develop scalable technology, Baker has become one of just 15 recipients worldwide from more than 800 applications.
“We’re using wearables to actually develop algorithms that can predict when someone is going to start wandering or is going to get up and have a fall or hit another resident in the nursing home,” she said.
“We’ve got it down to between five and 15 minutes, so a carer or family member can anticipate that something’s going to happen.”
Baker said using AI to help preempt when to use music was one thing, but then what order the music should come in, what kind of music and how to be sensitive to the specific symptoms of people with dementia created further challenges they continue to work on.
Simone Dalla Bella, co-director of the BRAMS laboratory at the University of Montreal is conducting research focused on rhythm interventions for patients with various disorders, including Parkinson’s disease.

Simone Dalla Bella
The interventions include rhythmic serious games such as Beat Workers, and mobile apps such as BeatMove, developed by the start-up BeatHealth that Dalla Bella co-founded.
For example, BeatMove can adjust music tempo to help Parkinson’s patients walk more effectively.
“Imagine that you have music in the background that you chose, and the music is going a bit faster than you, so it motivates you to run a bit faster.
“But then if you’re tired and you slow down, the music will follow you gently as if you were running or walking with a theoretical partner,” he said.
“A clinical trial is currently ongoing in France to test a large group of patients with Parkinson’s who basically take the app outside in a park, they use it, and we are seeing beneficial effects of that kind of intervention.”
Navigating music licensing challenges
The prospect of music-powered therapy is rather inspiring and life-affirming. Providing outcomes for patients with debilitating conditions in a non-invasive way is certainly a noble cause for academics and entrepreneurs alike to take up.
However, what many might not have considered is how these medical applications acquire and manage music rights.
Virginie Chelles, VP and Global Head of Marketing and Communications for music licensing and technology company Tuned Global, described the complexity facing these innovators.
In working with medical technology clients, Chelles highlighted that while founders deeply understand the science and tech behind their products and projects, they often have no knowledge of music industry operations.
“When it comes to us, there is a whole new industry, being the music industry which has little or no connection with the medical industry, [which in itself also] has a lot of regulation,” she said.
In the medical music space, Tuned Global currently works with MediMusic, a UK startup that uses AI to analyse brain responses and select music for anxiety and pain management.
Companies like MediMusic are obviously performing powerful and important work, but in cases where they are not up to speed on all of the requirements to correctly licence music, they are adding layers of risk to an already compliance-heavy environment.

Virginie Chelles
“They’re dealing with the legal side of medicine in being able to have it delivered in NHS Hospitals in the UK, and going for trials and all that is involved.
“There is a lot of paperwork to do there,” Chelles said. “But then, if they play the wrong track, [a] track that was not licensed, the business is in trouble.”
“[They would be looking at lawsuits], and they wouldn’t be paying the rights to the right people. There are master rights, there’s publishing rights. [So they think], ‘How do I do that? How do I find the right tracks?’.”
Often in these kinds of apps, an AI personalisation solution will drive the selection of tracks that resonate with certain patients, so another challenge for medtech clients in knowing the extent of what other tracks they will need access to.
Companies must also consider whether their licenses permit training medical algorithms on music assets.
“Thousands of tracks are released every day, and [if you look at what’s being produced] with AI. It’s even more,” she said.
“Many companies don’t need millions of tracks. If you work on dementia, just working on a back catalogue, like the catalog that makes sense for these people when they were in their 20s.
“For us, it helped us to understand what you need to license the right catalog, rather than millions of tracks, because accessing millions of tracks is a lot of money in storage and in processing.”
Understanding music licensing early in the innovation process
For medtech companies wanting to leverage music, Chelles was direct about the challenges and decisions they face when they first approach music licensing.
A lot of consideration needs to be made about how much music they need, what kind, whether they need commercial music or production music and more.
When MediMusic first engaged Tuned Global, these considerations presented a big challenge.
“Because licensing music is not a science. It’s not predictable, but we can definitely help,” she said.
Elaborating further, Chelles said that companies tended to be more successful when they addressed music licensing early in development rather than treating it as an afterthought.
“It’s going to take as much time to build the music and the licensing and compliance technology as building your medical device or app or science behind it,”
“Talk to a music expert early on, it can be us, but it can also be entertainment lawyers or licensing specialists that are going to be able to help from the beginning … to just understand what it is about.
“We can also help them to build their business case to pitch to those labels, because this can be quite strategic depending on the label and their current objectives.
“Making big pitches without understanding them or the broader environment could cost a lot of time and money if they don’t sign you up right away.
“Being able to demonstrate and communicate value in this industry on the industry’s terms is really important for success, so if you can work with people that have these relationships and can engage with them it’s very helpful.”
Working with an established music technology company can help medtech startups navigate label negotiations. Labels recognise that companies already working with licensing specialists have typically secured funding and understand the commercial requirements.
“[The labels are] like, okay, they are legit, because if Tuned Global can work with them, they already have the funding and they understand what they’re doing,” Chelles said.
Securing licensing agreements is only the first step. Companies then need backend technology to access the actual tracks.
Tuned Global maintains 190 million tracks, with the catalog growing daily.
Companies must negotiate separately with both master rights holders (the record labels) and publishers who represent musicians and writers.
Commercialising research and innovation
Neither researcher came from a background that prepared them for music industry negotiations.
Despite publishing in The Lancet and Nature and securing major medical research grants, Baker found music licensing remained unfamiliar territory.
Dalla Bella received more than $USD 3.5m in European research funding but similarly had no training in navigating music rights.
Startup activity at universities is growing, but this has not always been the case.
Baker noted that while the institutions themselves were very supportive and really wanted to push research innovations into the market, there still exists some commercialisation stigmas among some researchers.
“For some researchers, commercialising your research is kind of almost like a dirty word.
“To them it’s like you’re not being true to the science if you want to actually make a company and do something with this,” she said.
Dalla Bella described how moving from pure research into commercial applications required stepping outside his comfort zone.
“Sometimes in science, we’re very closed, right?
“We do work just in science, in our niche, we are happy with what we do, but then you have to go beyond your comfort zone to start to work with engineers and start to work with a startup company,” he said.
“[I’ve seen for a lot of people] it took time to build this collaboration, this common language, and to be able to work together. After a certain amount of time, you discover the real potential of doing that.”
The future of tech powered music therapies
The medical music technology sector is an exciting and expanding space.
As more innovators enter the industry, the intersection between healthcare regulation and music licensing will likely require more standardised frameworks and understanding of the complexities so they aren’t bogged down or exposed to complications that could cut their journey to provide care short.
For now, companies navigating both industries must build relationships with experts in each domain.
The medical science may be groundbreaking, but without proper music licensing infrastructure, therapeutic applications cannot reach patients or compensate the artists whose work makes treatment possible.
About Tuned Global
Tuned Global is the leading data-driven cloud and software platform that empowers businesses to integrate commercial music into their apps or launch complete streaming experiences using advanced APIs, real-time analytics, licensing solutions, and customisable white-label apps.
Our turnkey solutions for music, audio, and video — coupled with a broad ecosystem of third-party music tech integrations — make us the most comprehensive platform for powering any digital music project. We streamline complexities in licensing, rights management, and content delivery, enabling rapid innovation and bringing new ideas to life.
Since 2011, we’ve supported 40+ companies in 70+ countries — across telecom, fitness, media, aviation, and more — to deliver innovative music experiences faster and more cost-effectively.
For more information, visit www.tunedglobal.com.
Insight
Women urged to be wary of menopause misinformation on social media

Women are being urged to seek evidence-based advice and avoid menopause misinformation shared on social media.
A seminar co-hosted by the World Health Organization (WHO) mainly examined what is known about the cognitive effects of menopause and current research in the field worldwide.
Dr Nicole Jaff, a South African academic and certified menopause practitioner, said research into menopause and its effects was now at a peak.
She said: “There’s a lot of information out there.
“But I would say please look for the evidence-based information, not for the influencers and the misinformation, but those who are giving guidelines, who are giving information.”
Jaff highlighted research into cognitive changes during menopause and how some women experience brain fog, a term for difficulties with memory, concentration and clear thinking.
She said: “I’m very excited about the non-hormonal treatments that are now available, especially for women who could never take hormone therapy because of breast cancers and various cancers, who can now take it.
“I’m extremely excited about people who are standing up for evidence-based medicine, for science, who are actually fighting back against a lot of the social media and influencers who are not giving evidence-based information and making life very difficult for women because they think they should be forever young or buying this or buying that.”
Jaff advised women and healthcare workers to read new guidelines recently issued by the International Menopause Society. They are available free to download from its website.
The seminar also heard from Professor Aimee Spector, professor of clinical psychology of ageing at University College London.
She raised similar concerns about misinformation, particularly claims linking hormone replacement therapy, known as HRT, to dementia. Some claims suggest HRT reduces dementia risk, while others suggest it increases the risk.
Spector said: “I think there’s also lots of misinformation.
“And I think that there’s huge variations in how even professionals and doctors interpret this information.”
She was part of an international research team commissioned by the WHO last year to assess published studies on the issue.
The institutions involved also included the Global Brain Health Institute at Trinity College Dublin.
Spector said: “The first thing to say is that the quality of evidence was very low.
“Nine out of the 10 studies we looked at were observational, which means that you’re observing patterns over time. But you don’t necessarily know whether that’s due to the hormone therapy or not.
“Our overall recommendation was that there’s insufficient evidence for menopause hormone therapy in terms of either increasing or reducing the risk of dementia. In other words, we don’t know either way.”
Spector said women should therefore decide whether to use HRT to treat menopause symptoms rather than based on concerns about dementia.
She said: “It’s recommended for menopause symptoms, but it’s not recommended to reduce dementia. And I think a lot of people are saying that.”
The Menopause on the Brain webinar was part of an ongoing series hosted by the WHO and other global health agencies.
Insight
Endometriosis musical set for Edinburgh Fringe stage

An endometriosis musical by two US writers will debut at the Edinburgh Festival Fringe in August.
“Endometriosis: The Musical” follows Jane, a woman trying to discover why she is living with chronic pain.
Maria Bartholdi and Kristin Stowell first developed the production for the 2022 Minnesota Fringe Festival.
The full show premiered at Theater in the Round in Minneapolis in 2025.
Stowell said the play drew on personal experience, although neither writer realised it at the time.
“So it’s like my goal to let women see themselves in this who are dealing with this and have a question they can bring back to their doctor,” she said.
“Like, could it be endometriosis?”
Bartholdi said she did not realise she might have the condition herself until after the play premiered.
“This show helped diagnose me, which I think is just one of the miraculous things that we hope this the show does for other people as well,” Bartholdi said.
Dr Wendy VanBuren, a radiologist at Mayo Clinic in Rochester, said she was a fan of the musical and its role in raising awareness of a common but underdiagnosed disease.
“Cells that are similar to but not identical to the cells that comprise the lining of the uterus, the inside of the uterus, are located outside the uterus,” said VanBuren.
“When they’re outside the uterus, there isn’t the right environment to deal with that. So basically, what you get is bleeding, and then you get inflammation.”
Roughly one in seven women live with the disease, and receiving a diagnosis can take nearly a decade.
Insight
Johnson & Johnson offers to pay US$5.5bn to settle talc cancer lawsuits

Johnson & Johnson has offered an estimated US$5.5bn settlement covering about 76,000 claims that its talc products caused ovarian cancer.
The proposed agreement could end a contentious legal dispute over the company’s baby powder and other talc-based products that has lasted around a decade.
Johnson & Johnson said the settlement covers claims consolidated in a federal court in New Jersey and related cases in state court.
The claims represent nearly all the remaining talc cases against the US multinational, according to the company.
Johnson & Johnson has previously settled most claims alleging that its talc contained asbestos and caused mesothelioma.
Mesothelioma is a rare cancer affecting the lining of organs, most commonly the lungs, and is usually linked to asbestos exposure.
Law firms representing claimants confirmed the proposed deal, describing it as a good resolution after around 10 years of litigation.
The agreement must be accepted by 95 per cent of ovarian cancer claimants in state or federal court before it becomes final.
Erik Haas, vice-president of litigation at Johnson & Johnson, said the claims were “meritless” and that the company was willing to settle to bring the litigation to a close.
“While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Haas said.
The company expects to pay US$3bn in 2027, with further payments due in 2028.
The deal could be worth more, depending on how many people take part in the settlement.
Chris Seeger, a lawyer representing around 2,500 clients with talc claims who helped negotiate the agreement, said Johnson & Johnson could ultimately pay US$7bn or more.
The settlement assigns specific values to qualifying ovarian cancer claims but does not cap the company’s total payout.
“We got a fair settlement, and our clients are going to be happy with it,” Seeger said.
Johnson & Johnson reached the agreement after a series of court victories, including wins in individual trials and successful efforts to disqualify claimants’ lawyers from the litigation.
The company also secured court rulings against experts used by claimants to support their cases.
A federal judge last week questioned whether individual claimants could prove that talc had specifically caused their ovarian cancer.
Johnson & Johnson has consistently denied that its talc products caused cancer, maintaining that the products were safe and did not contain asbestos.
The company stopped selling talc-based baby powder in the US in 2020 and switched to a cornstarch-based product.
Litigation resumed in March 2025 after being paused for more than three years while Johnson & Johnson pursued a bankruptcy strategy known as the “Texas two step”.
The company filed three bankruptcies through a shell-company subsidiary in an attempt to settle the cases. Each bankruptcy was dismissed.
Before the bankruptcy attempts, Johnson & Johnson had a mixed record in talc trials.
These included a multibillion-dollar verdict for 22 women who said baby powder caused their ovarian cancer, alongside trials won by Johnson & Johnson and other verdicts later reduced on appeal.
Unlike the proposed bankruptcy settlements, the latest agreement applies only to existing claims and does not cover future lawsuits.
Seeger said excluding future claims made more money available for current claimants than the bankruptcy proposal and would allow all claims to be paid within 18 months rather than over more than a decade.
News2 days agoUK femtech investment surges 194% in a decade, research finds
Entrepreneur2 weeks agoFertility startup American Baby Company secures US$4m
Insight2 weeks agoNatural Cycles receives sixth FDA clearance for fertility algorithm
Wellness6 days agoCancer patient receives ‘landmark’ treatment in world-first
Insight2 weeks agoExperimental treatment significantly slows progression of fatal brain disease in women, study finds
Sponsored Content2 weeks agoThe room is filling up at WHW Europe 2026 with super early bird pricing ending this Friday
Insight1 week agoJohnson & Johnson offers to pay US$5.5bn to settle talc cancer lawsuits
News2 weeks agoPlanetary Health Diet lowers heart risk in older women, study finds












1 Comment